INTRODUCTION {#s1}
============

Osteoblasts are important for the bone formation and remodeling \[[@R1], [@R2]\]. Yet, these mesenchymal progenitor cells-derived cells are also the main target cells of oxidative stress \[[@R1], [@R2], [@R5]\]. Increased reactive oxygen species (ROS) production will lead to oxidative stress, causing osteoblast cell damage and apoptosis \[[@R6], [@R7]\]. Hydrogen peroxide (H~2~O~2~) is often added to cultured osteoblasts to establish a cellular model of osteonecrosis \[[@R8]--[@R11]\]. For many years, our group \[[@R12]--[@R15]\] has been focusing on indentifying novel molecular targets to promote osteoblast cell survival.

AMP-activated protein kinase (AMPK) is a master regulator of cellular metabolism and energy \[[@R16]\]. It plays a pivotal function in maintaining cell energy balance \[[@R16]\]. Existing studies have suggested that AMPK activation could also promote cell survival \[[@R17]\]. Recent literatures investigated the potential functions of AMPK in osteoblasts, and demonstrated that activating AMPK, either genetically or pharmacologically, could protect osteoblasts from oxidative stress and dexamethasone \[[@R12], [@R18]--[@R20]\]. Therefore, AMPK is a valuable pro-survival target at least in osteoblasts \[[@R12], [@R18]--[@R20]\].

Multiple AMPK activators of different mechanisms of actions have been developed thus far, many of them activate AMPK though increasing the AMP:ATP ratio, such as AICAR \[[@R21], [@R22]\]. Others, however, provoke AMPK activation by directly inducing AMPKα1 phosphorylation at Thr-172, *i.e*. Compound 13 \[[@R21]--[@R24]\]. Recent studies have developed GSK621 as a novel AMPK activator \[[@R25]\]. Its potential activity in osteoblasts has not been tested thus far. In this study, we show that GSK621 activates AMPK signaling and potentially inhibits H~2~O~2~-induced oxidative damages in cultured osteoblasts.

RESULTS {#s2}
=======

GSK621 protects osteoblasts from H~2~O~2~ {#s2_1}
-----------------------------------------

The current study aims to understand the potential effect of GSK621 on oxidative-stressed osteoblasts. CCK-8 viability results in Figure [1A](#F1){ref-type="fig"} demonstrated that H~2~O~2~ (250 μM, 24 hours) treatment in MC3T3-E1 osteoblastic cells \[[@R15]\] induced over 50% cell viability reduction. Significantly, co-treatment with GSK621 at 2.5-25 μM dramatically attenuated H~2~O~2~-induced MC3T3-E1 cell viability reduction (Figure [1A](#F1){ref-type="fig"}). LDH release results in Figure [1B](#F1){ref-type="fig"} confirmed H~2~O~2~ (250 μM)-induced MC3T3-E1 cell death, which was again largely attenuated with co-treatment of GSK621 (2.5-25 μM). Meanwhile, H~2~O~2~ (250 μM)-induced MC3T3-E1 cell apoptosis, tested by Histone DNA ELISA assay \[[@R12], [@R13]\], was also significantly alleviated by GSK621 co-treatment (Figure [1C](#F1){ref-type="fig"}). The anti-H~2~O~2~ activity of GSK621 in MC3T3-E1 cells was dose-dependent (Figure [1A-1C](#F1){ref-type="fig"}). At a low concentration (1 μM), GSK621 was invalid to inhibit H~2~O~2~ damages (Figure [1A-1C](#F1){ref-type="fig"}). Notably, treatment with GSK621 alone at tested concentrations failed to induce survival change (Figure [1D](#F1){ref-type="fig"}) and apoptosis (Data not shown) in MC3T3-E1 cells.

![GSK621 protects osteoblasts from H~2~O~2~\
MC3T3-E1 osteoblastic cells **A-D**. or the primary murine osteoblasts **E-G**. were treated with hydrogen peroxide ("H~2~O~2~", 250 μM) with/out GSK621 at applied concentration, cells were then cultured for additional 16/24 hours; Cell survival (CCK-8 assay, A, D and E), cell death (LDH release assay, B and F) and apoptosis (Histone DNA ELISA assay, C and G) were tested. Data are shown as mean (n=5) ± standard deviation (SD). "Ctrl" stands for medium treatment control (Same for all figures). Experiments in this figure were repeated for three times, and similar results were obtained. \**p*\<0.05 *vs*. H~2~O~2~ only group.](oncotarget-08-10543-g001){#F1}

Using the methods described \[[@R12]--[@R15]\], we also established primary murine osteoblasts. H~2~O~2~ (250 μM) treatment in these primary cells also induced viability reduction (Figure [1E](#F1){ref-type="fig"}), cell death (Figure [1F](#F1){ref-type="fig"}) and apoptosis (Figure [1G](#F1){ref-type="fig"}). Remarkably, GSK621 (10 μM) co-administration significantly alleviated H~2~O~2~-induced damages of the primary osteoblasts (Figure [1E-1G](#F1){ref-type="fig"}). GSK621 (10 μM) alone again didn't affect survival and apoptosis of the primary cells (Figure [1E-1G](#F1){ref-type="fig"}). These results show that GSK621 indeed protects osteoblasts from H~2~O~2~.

GSK621-mediated osteoblast cytoprotection requires AMPK activation {#s2_2}
------------------------------------------------------------------

GSK621 is a newly-developed AMPK activator \[[@R25]--[@R27]\], we therefore tested AMPK signaling in GSK621-treated cells. As shown in Figure [3A](#F3){ref-type="fig"}, treatment with GSK621 (at 2.5-25 μM, 2 hours) in MC3T3-E1 cells induced significant AMPK activation, which was tested by phosphorylation ("p") of AMPKα1 (Thr-172) and its major downstream target protein ACC (acetyl-CoA carboxylase, Ser-79) \[[@R12]\]. Expression of total AMPKα1 and ACC was not changed following the GSK621 treatment (Figure [3A](#F3){ref-type="fig"}). To study the link between GSK621-induced AMPK activation and osteoblast cytoprotection, shRNA strategy \[[@R12]\] was applied to silence AMPK signaling. In the study, a total of three different lentiviral AMPKα1 shRNAs ("Seq-1/-2/-3") were designed (See Methods), and each of them potently downregulated AMPKα1 in MC3T3-E1 cells (Figure [2B](#F2){ref-type="fig"}). Consequently, GSK621-induced AMPK activation, or p-AMPKα1/p-ACC, was almost abolished in AMPKα1-silenced cells (Figure [2B](#F2){ref-type="fig"}). Importantly, although the AMPKα1 shRNAs alone didn't affect MC3T3-E1 cell survival (Figure [2C](#F2){ref-type="fig"}), they almost abolished GSK621-mediated osteoblast cytoprotection against H~2~O~2~ (250 μM) (Figure [2D](#F2){ref-type="fig"} and [2E](#F2){ref-type="fig"}). In another words, GSK621 was pretty much invalid against H~2~O~2~ when AMPKα1 was silenced (Figure [2D](#F2){ref-type="fig"} and [2E](#F2){ref-type="fig"}).

![GSK621-mediated osteoblast cytoprotection requires AMPK activation\
MC3T3-E1 cells were treated with GSK621 at applied concentrations for 2 hours, expression of listed proteins was shown **A**. MC3T3-E1 cells, expressing listed lentiviral AMPKα1 shRNA ("Seq-1/-2/3") or scramble control shRNA ("sc-sh"), were subjected to Western blotting assay of listed proteins **B**.; These cells were also treated with/out H~2~O~2~ (250 μM) or plus GSK621 (10 μM) for 24 hours; Cell viability (CCK-8 assay, **C**. and **D**.) and cell death (LDH release assay, **E**. were tested. Primary murine osteoblasts, transfected with indicated AMPKα1 siRNA ("Seq-1/-2") or scramble control siRNA ("sc-si"), were treated with GSK621 (10 μM) for 2 hours, expression of listed proteins was tested **F**. Cells were also stimulated with H~2~O~2~ (250 μM) for 24 hours, and cell survival **G**. and cell death **H**. were tested. AMPKα1 ("p-" and total) or p-ACC were quantified. Data are shown as mean (n=6) ± SD. Experiments in this figure were repeated for three times, and similar results were obtained. ^\#^*p*\<0.05 vs. "sc-sh"/"sc-si" group.](oncotarget-08-10543-g002){#F2}

![AMPKα1 dominant negative mutation abolishes GSK621-induced osteoblast cytoprotection\
Neomycin-selected stable MC3T3-E1 cells expressing dominant negative AMPKα1 (T172A) construct ("dn-AMPKα1", Flag-tagged) or the empty vector (pSuper-Flag, "Vec") were treated with GSK621 (10 μM) for 2 hours, expression of listed proteins was tested **A**. Cells were also subjected to H~2~O~2~ (250 μM) stimulation; Cell survival (CCK-8 assay, **B**. Cell death (LDH release assay, **C**. and apoptosis (Histone-DNA ELISA assay, **D**. were tested. Data are shown as mean (n=4) ± SD. p-AMPKα1 and p-ACC were quantified. Experiments in this figure were repeated for three times, and similar results were obtained. ^\#^*p*\<0.05 vs. "Vec" group.](oncotarget-08-10543-g003){#F3}

In the primary murine osteoblasts, two non-overlapping AMPKα1 siRNAs ("Seq-1/-2") were utilized to knockdown AMPKα1. As demonstrated, the two applied siRNAs knocked down AMPKα1 in the primary cells (Figure [2F](#F2){ref-type="fig"}). GSK621 (10 μM, 2 hours)-induced AMPK activation, or p-AMPKα1/p-ACC, was also dramatically inhibited with AMPKα1 siRNA knockdown (Figure [2F](#F2){ref-type="fig"}). Similarly, GSK621 was also largely ineffective when AMPKα1 was silenced (Figure [2G](#F2){ref-type="fig"} and [2H](#F2){ref-type="fig"}). Seq-1 AMPKα1 siRNA was slightly more efficient than Seq-2 siRNA in downregulating AMPKα1 (Figure [2F](#F2){ref-type="fig"}). It was also more efficient in shutting down GSK621-mediated cytoprotection (Figure [2G](#F2){ref-type="fig"} and [2H](#F2){ref-type="fig"}). Together, these results indicate that AMPK activation is required for GSK621-induced osteoblast cytoprotection against H~2~O~2~.

AMPKα1 dominant negative mutation abolishes GSK621-induced osteoblast cytoprotection {#s2_3}
------------------------------------------------------------------------------------

To further confirm the requirement of AMPK activation in GSK621-induced actions in osteoblasts, a dominant negative AMPKα1 (T172A) construct ("dn-AMPKα1", Flag-tagged) \[[@R12]\] was utilized. The mutant AMPKα1 was introduced to MC3T3-E1 cells. Via neomycin selection, stable MC3T3-E1 cells with the mutant AMPKα1 were established. Western blotting assay results in Figure [3A](#F3){ref-type="fig"} confirmed dn-AMPKα1 expression in the stable cells. Further, GSK621 (10 μM, 2 hours)-induced AMPK activation (p-AMPKα1/p-ACC) was almost abolished in dn-AMPKα1-expressing cells (Figure [3A](#F3){ref-type="fig"}). More importantly, GSK621-induced osteoblast protection against H~2~O~2~ was also largely inhibited with AMPKα1 mutation (Figure [3B-3D](#F3){ref-type="fig"}). GSK621-induced pro-survival (Figure [3B](#F3){ref-type="fig"}), anti-death (Figure [3C](#F3){ref-type="fig"}) and anti-apoptosis (Figure [3D](#F3){ref-type="fig"}) actions in H~2~O~2~-treated cells were significantly attenuated. These results again confirm that AMPK activation is required for GSK621-mediated osteoblast cytoprotection against H~2~O~2~.

Forced-activation of AMPK protects osteoblasts from H~2~O~2~, taking over GSK621's actions {#s2_4}
------------------------------------------------------------------------------------------

Next, a constitutively-active AMPKα1 (T172D) construct ("ca-AMPKα1", Flag-tagged) \[[@R12]\] was introduced to MC3T3-E1 cells, and stable cell line with the ca-AMPKα1 was selected by puromycin. Western blotting results in Figure [4A](#F4){ref-type="fig"} confirmed expression of ca-AMPKα1 in the stable cells. As expected, AMPK was constitutively active in these cells, and p-AMPKα1 and p-ACC level was high (Figure [4A](#F4){ref-type="fig"}). Compared to the vector control MC3T3-E1 cells, the ca-AMPKα1-expressing cells were protected from H~2~O~2~, presenting with significantly less viability reduction (Figure [4B](#F4){ref-type="fig"}) and cell death (Figure [4C](#F4){ref-type="fig"}) after H~2~O~2~ treatment. Significantly, in ca-AMPKα1-expressing MC3T3-E1 cells, GSK621 (10 μM) could not further protect cells from H~2~O~2~ (Figure [4B](#F4){ref-type="fig"} and [4C](#F4){ref-type="fig"}). Thus, ca-AMPKα1 expression took over GSK621's actions and inhibited H~2~O~2~ damages in MC3T3-E1 cells. These results against indicate that activation of AMPK is required for GSK621-mediated osteoblast cytoprotection.

![Forced-activation of AMPK protects osteoblasts from H~2~O~2~, taking over GSK621's actions\
Puromycin-selected stable MC3T3-E1 cells, expressing the constitutively-active AMPKα1 (T172D) construct ("ca-AMPKα1", Flag-tagged) or the empty vector (pSuper-Flag, "Vector"), were subjected to Western blotting assay of listed proteins **A**. Above cells were also treated with H~2~O~2~ (250 μM) or plus GSK621 (10 μM) for 24 hours; Cell survival (CCK-8 assay, **B**. and cell death (LDH release assay, **C**. were tested. Data are shown as mean (n=4) ± SD. p-AMPKα1 and p-ACC were quantified. Experiments in this figure were repeated for four times, and similar results were obtained. ^\#^*p*\<0.05 vs. "Vector" group.](oncotarget-08-10543-g004){#F4}

GSK621 increases NAPDH content and inhibits H~2~O~2~-induced oxidative stress {#s2_5}
-----------------------------------------------------------------------------

Recent studies have proposed an anti-oxidant function of AMPK under many stress conditions. Activated AMPK may increase nicotinamide adenine dinucleotide phosphate (NADPH) content to inhibit ROS production and accumulation \[[@R19], [@R20], [@R28], [@R29]\]. Here, GSK621 treatment also increased NADPH level in MC3T3-E1 cells (Figure [5A](#F5){ref-type="fig"}), which was blocked by AMPKα1 shRNA knockdown or dominant negative mutation (Figure [5A](#F5){ref-type="fig"}). Intriguingly, H~2~O~2~-induced ROS production was also largely inhibited with co-treatment of GSK621 (Figure [5B](#F5){ref-type="fig"}). More importantly, the anti-oxidant activity by GSK621 was nullified with AMPKα1 shRNA or dominant negative mutation (Figure [5B](#F5){ref-type="fig"}). Therefore, GSK621 inhibits H~2~O~2~-induced ROS production in an AMPK-dependent manner. In the primary murine osteoblasts, GSK621 (10 μM) similarly increased NAPDH content (Figure [5C](#F5){ref-type="fig"}) and inhibited H~2~O~2~-induced ROS production (Figure [5C](#F5){ref-type="fig"}). These results show that GSK621 increases NAPDH content and inhibits H~2~O~2~-induced oxidative stress in osteoblasts.

![GSK621 increases NAPDH content and inhibits H~2~O~2~-induced oxidative stress\
MC3T3-E1 cells, expressing scramble control shRNA ("sc-sh"), AMPKα1 shRNA (Seq-1, "sh AMPKα1") or dominant negative AMPKα1 (T172A) ("dn-AMPKα1"), were treated with GSK621 (10 μM) or plus H~2~O~2~ (250 μM) for applied time; Relative NAPDH level **A**. and ROS content **B**. were tested by the listed assays. The primary murine osteoblasts were treated with GSK621 (10 μM) or plus H~2~O~2~ (250 μM) for applied time, relative NAPDH level **C**. and ROS content **D**. were tested. Data are shown as mean (n=3) ± SD. Experiments in this figure were repeated for four times, and similar results were obtained. \**p*\<0.05 vs. "Ctrl" group. ^\#^*p*\<0.05 vs. "H~2~O~2~" only group.](oncotarget-08-10543-g005){#F5}

GSK621 activates cytoprotective autophagy in osteoblasts {#s2_6}
--------------------------------------------------------

AMPK could also provoke autophagy to promote cell survival \[[@R19], [@R30], [@R31]\]. AMPK is shown to directly phosphorylate and activate its key downstream Ulk1 to initiate autophagy, which is cytoprotective \[[@R19], [@R30], [@R31]\]. Here, in both MC3T3-E1 cells (Figure [6A](#F6){ref-type="fig"}) and primary murine osteoblasts (Figure [6B](#F6){ref-type="fig"}), GSK621 (10 μM, 2 hours) induced significant Ulk1 phosphorylation at Ser-317 (Results were quantified), the site that can only be activated by AMPK \[[@R30]\]. Subsequently, expression of autophagy-associated proteins, including Beclin-1, autophagy-related homologue 5 (ATG-5) and light chain 3B-II (LC3B-II), was significantly increased, while p62 was degradated (See quantified results in Figure [6C-6D](#F6){ref-type="fig"}). These results suggested significant autophagy activation in GSK621-treated cells \[[@R32]--[@R34]\]. Remarkably, as shown in Figure [6E](#F6){ref-type="fig"} and [6F](#F6){ref-type="fig"}, GSK621 (10 μM)-induced osteoblast cytoprotection against H~2~O~2~ was compromised in the presence of autophagy inhibitor 3-methyaldenine (3-MA) and chloroquine (Cq) \[[@R32], [@R35]\]. Therefore, GSK621's actions in MC3T3-E1 cells was weakened when autophagy was pharmacologically inhibited (Figure [6E](#F6){ref-type="fig"} and [6F](#F6){ref-type="fig"}). These results indicate that GSK621 activates cytoprotective autophagy in osteoblasts.

![GSK621 activates cytoprotective autophagy in osteoblasts\
MC3T3-E1 cells (A and C) or the primary murine osteoblasts (B. and D.) were treated with GSK621 (10 μM) for designated time; Expression of listed proteins was tested by Western blotting assay, results were quantified (**A-D**). MC3T3-E1 cells, pre-treated for 1 hour with 3-methyladenine (3-MA, 0.5 mM) or chloroquine (Cq, 10 μM), were then treated with H~2~O~2~ (250 μM) or plus GSK621 (10 μM) for 24 hours; Cell viability (CCK-8 assay, **E**) and cell death (LDH release assay, **F**) were tested. Data are shown as mean (n=4) ± SD. Experiments in this figure were repeated for four times, and similar results were obtained. ^\#^*p*\<0.05 vs. "GSK621" only group.](oncotarget-08-10543-g006){#F6}

DISCUSSION {#s3}
==========

The results of the current study suggest that AMPK activation is required for GSK621-induced osteoblast cytoprotection against H~2~O~2~. shRNA stable knockdown of AMPKα1 almost completely blocked GSK621-induced AMPK activation and osteoblast cytoprotection. Similarly, AMPK in-activation via intruding the dominant negative mutant AMPKα1 (T172A) also nullified GSK621-mediated anti-H~2~O~2~ actions in osteoblasts. Reversely, forced-activation of AMPK via introducing the ca-AMPKα1 mimicked GSK621's actions and alleviated H~2~O~2~-induced osteoblast cell death. Remarkably, GSK621 was unable to further protect osteoblasts with ca-AMPKα1 expression. All these results imply that activation of AMPK is indispensable for GSK621-induced cytoprotection in osteoblasts.

Several mechanisms are responsible for AMPK-mediated cytoprotection. For example, AMPK could activate cytoprotective autophagy, which recycles cellular components to provide nutrition for cell survive \[[@R36], [@R37]\]. AMPK is shown to directly phosphorylate Ulk1 to initiate cell autophagy \[[@R36], [@R37]\]. Further, AMPK could also function as an anti-oxidant protein, via increasing NADPH content and limiting ATP consumption \[[@R28]\]. In addition, under starvation condition, AMPK activation could also protect cells through in-activating mTOR complex 1 (mTORC1) \[[@R38]\].

Here, we found that GSK621 induced NADPH production to inhibit H~2~O~2~-induced ROS production in osteoblasts. Such effects by GSK621 were dependent on AMPK activation. As AMPKα1 dominant negative mutation (T172A) or shRNA stable knockdown almost abolished GSK621-induced NADPH production and ROS scavenging activity. Our results here are consistent with recent findings showing ROS clearance by several different AMPK activators in osteoblasts \[[@R12], [@R18], [@R19]\]. Meanwhile, we showed that GSK621 treatment in the osteoblasts also activated cytoprotective autophagy, which was evidenced by Ulk1 phosphorylation at Ser-317, upregulation of Beclin-1, ATG-5 and LC3B-II, as well as degradation of p62. Importantly, autophagy inhibitors alleviated GSK621-mediated osteoblast cytoprotection. Together, ROS clearance and autophagy activation could be two major downstream targets of AMPK in mediating GSK621's cytoprotection in osteoblasts. Although, the detailed underlying mechanisms may warrant further investigations.

MATERIALS AND METHODS {#s4}
=====================

Chemicals, regents and antibodies {#s4_1}
---------------------------------

GSK621 was purchased from Gao-Chem (Shanghai, China). H~2~O~2~, puromycin, 3-methyaldenine (3-MA) and chloroquine (Cq) were purchased from Sigma Chemicals (St. Louis, MO). Anti-AMPKα1, acetyl-CoA carboxylase (ACC) and Beclin-1, autophagy-related homologue 5 (ATG-5), light chain 3B-II (LC3B-II), p62 and Erk1/2 antibodies were purchased from Santa Cruz Biotech (Santa Cruz, CA). Antibodies against phospho(p)-AMPKα1 (Thr 172), p-ACC (Ser 79), p-S6K1 (Thr-389), p-S6 (Ser-235/236) and total S6K1 were obtained from Cell Signaling Tech (Denver MA).

Culture of MC3T3-E1 osteoblastic cells {#s4_2}
--------------------------------------

The murine calvaria-derived osteoblastic-like MC3T3-E1 cells were cultured and differentiated as described in our previous studies \[[@R13], [@R14]\].

Isolation and primary culture of murine osteoblasts {#s4_3}
---------------------------------------------------

The isolation and primary culture of murine osteoblasts were described previously \[[@R13], [@R14]\]. The animal protocols were approved by Institutional Animal Care and Use Committee (IACUC) and Institutional Ethics Committee.

Cell survival assay {#s4_4}
-------------------

Cell Counting Kit-8 (CCK-8, Dojindo Laboratories, Kumamoto, Japan) was applied to test survival of osteoblasts with applied treatment/s. The detailed protocol was described in our previous studies \[[@R13], [@R14]\].

Cell apoptosis assay {#s4_5}
--------------------

To test cell apoptosis, the histone-DNA ELISA plus kit (Roche, Palo Alto, CA) \[[@R13], [@R14]\] was applied. ELISA OD at 450 nm was recorded as the indicator of cell apoptosis \[[@R13], [@R14]\].

Cell death assay {#s4_6}
----------------

Analyzing cell death by measuring lactate dehydrogenase (LDH) content in the conditional medium was through a two-step enzymatic reaction LDH assay kit (Takara, Tokyo, Japan), as described \[[@R13], [@R14]\].

Western blotting assay {#s4_7}
----------------------

As described previously \[[@R13], [@R14]\], 30 μg protein lysates per sample were separated by SDS-PAGE gel, and were transferred to the PVDF membranes. These blots were then blocked, and were subsequently incubated with primary and specific secondary antibodies. Protein bands were visualized via ECL reagents (Pierce, Shanghai, China). Band intensity of total gray was quantified via the ImageJ software \[[@R13], [@R14]\].

AMPKα1 stable knockdown {#s4_8}
-----------------------

A set of three different murine AMPKα1 shRNAs with non-overlapping sequences ("Seq-1/-2/-3", Genepharm, Shanghai, China) were constructed into the GV428 lentiviral vector (Genepharm), containing a puromycin-resistance gene and the Flag-tag. MC3T3-E1 cells were cultured with 50% confluence. The lentiviral shRNA (5 μL/mL) was added directly to the cultured cells for 24 hours. Cells were then subjected to puromycin (0.5 μg/ml) selection for the other 24 hours. Afterwards, AMPKα1 expression was detected by Western blotting assay. Control cells were infected with scramble control shRNA (Genepharm).

AMPKα1 mutation {#s4_9}
---------------

As described previously \[[@R12]\], the dominant negative AMPK-α1 (dn-AMPK-α1, T172A) construct or the constitutively-active mutant AMPKα1 (T172D, ca-AMPKα1) was transfected to the MC3T3-E1 cells (0.20 μg/mL \\ each) via the Lipofectamine 2000 reagent \[[@R39]\]. Stable cells were selected via neomycin (1 μg/mL, for dn-AMPK-α1) or puromycin (0.5 μg/mL, for ca-AMPKα1) for a total of two weeks. AMPKα1 expression and phosphorylation in the stable cells were detected by Western blotting assay.

AMPKα1 siRNA knockdown {#s4_10}
----------------------

The two non-overlapping murine AMPKα1 siRNAs ("Seq-1/Seq-2") and the scramble control siRNA were synthesized by Genepharm. Transient transfection (100 nM, 24 hours) was performed by the Lipofectamine 2000 reagents according to the manufacturer's instructions. Transfection efficiency was determined by Western blotting assay.

Assay of intracellular ROS level {#s4_11}
--------------------------------

The cellular reactive oxygen species (ROS) content was detected via the 2′, 7′-dichlorofluorescein diacetate (H2-DCFDA; Abcam, Shanghai, China) FACS method as described \[[@R18]\]. ROS level in treatment group was normalized to that of control group.

NADPH content assay {#s4_12}
-------------------

The intracellular NADPH content was tested via the previously described enzymatic cycling method \[[@R18], [@R19], [@R28]\]. Briefly, after treatment, twp million cells per sample were lysed, and the supernatant was incubated at 60°C for 30 min before NADP-cycling buffer plus glucose-6-phosphate dehydrogenase (G6PD, Sigma) \[[@R19]\] were added. Afterwards, glucose 6-phosphate (G6P, Sigma) was added to the mixture, and the change in absorbance at 570 nm was measured at 30°C. NADPH level in treatment group was normalized to that of control group.

Statistical analysis {#s4_13}
--------------------

Comparisons between groups were performed via one-way ANOVA and the Newman-Keuls test (SPSS 18.0). p values \< 0.05 were considered statistically significant.

CONCLUSIONS {#s5}
===========

Together, we conclude that targeted activation of AMPK by GSK621 significantly alleviates H~2~O~2~-induced damages in osteoblasts. GSK621 and other AMPK activators might have translational value for treatment oxidative stress-associated osteonecrosis.
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